A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study

NCT02175056 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
58
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Handok Inc.